Acetyl-HIST1H3A (K9) Antibody targets the acetylated lysine 9 residue on histone H3.1, a core component of nucleosomes. This modification is associated with open chromatin structures, facilitating transcription factor access and gene expression. The antibody demonstrates high specificity for mono-acetylated H3K9ac, distinguishing it from unacetylated histone H3 and other acetylation sites (e.g., K14) .
Epitope: Synthetic peptide derived from human histone H3.1 acetylated at K9 .
Clonality: Available as polyclonal (rabbit) and monoclonal (mouse) variants .
Purification: Affinity-purified via Protein A or peptide columns .
This antibody is widely employed in molecular biology and epigenetics research.
Species Reactivity: Human, mouse, rat .
H3K9ac is a hallmark of active chromatin. Acetyl-HIST1H3A (K9) Antibody has been instrumental in:
Mapping Transcriptional Activity: Identifying regions of open chromatin in cancer cells and stem cells .
Studying Epigenetic Dysregulation: Linking H3K9ac loss to silencing of tumor suppressor genes in cancers .
Cancer: Reduced H3K9ac levels correlate with poor prognosis in breast, lung, and colon cancers .
Neurodegeneration: Altered histone acetylation patterns observed in Alzheimer’s and Parkinson’s disease models .
Enzyme Interactions: Used to study histone acetyltransferase (HAT)/deacetylase (HDAC) activity .
Chromatin Remodeling: Demonstrates synergy with other histone modifications (e.g., H3K4me3) in transcriptional activation .
Emerging applications include: